These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34169247)

  • 1. Hepatic microbiome in healthy lean and obese humans.
    Suppli MP; Bagger JI; Lelouvier B; Broha A; Demant M; Kønig MJ; Strandberg C; Lund A; Vilsbøll T; Knop FK
    JHEP Rep; 2021 Aug; 3(4):100299. PubMed ID: 34169247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut Microbiota in Patients with Non-Alcoholic Fatty Liver Disease without Type 2 Diabetes: Stratified by Body Mass Index.
    Chuaypen N; Asumpinawong A; Sawangsri P; Khamjerm J; Iadsee N; Jinato T; Sutheeworapong S; Udomsawaengsup S; Tangkijvanich P
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.
    Nistal E; Sáenz de Miera LE; Ballesteros Pomar M; Sánchez-Campos S; García-Mediavilla MV; Álvarez-Cuenllas B; Linares P; Olcoz JL; Arias-Loste MT; García-Lobo JM; Crespo J; González-Gallego J; Jorquera Plaza F
    Rev Esp Enferm Dig; 2019 Apr; 111(4):275-282. PubMed ID: 30810328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fecal mycobiome in non-alcoholic fatty liver disease.
    Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
    J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.
    Yun Y; Kim HN; Lee EJ; Ryu S; Chang Y; Shin H; Kim HL; Kim TH; Yoo K; Kim HY
    PLoS One; 2019; 14(3):e0213692. PubMed ID: 30870486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.
    Duarte SMB; Stefano JT; Miele L; Ponziani FR; Souza-Basqueira M; Okada LSRR; de Barros Costa FG; Toda K; Mazo DFC; Sabino EC; Carrilho FJ; Gasbarrini A; Oliveira CP
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):369-384. PubMed ID: 29482963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
    Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Abdollahiyan S; Nabavi-Rad A; Keshavarz Azizi Raftar S; Monnoye M; Salarieh N; Farahanie A; Asadzadeh Aghdaei H; Zali MR; Hatami B; Gérard P; Yadegar A
    Sci Rep; 2023 Nov; 13(1):20584. PubMed ID: 37996480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis.
    Wahlang B; Alexander NC; Li X; Rouchka EC; Kirpich IA; Cave MC
    Toxicol Rep; 2021; 8():536-547. PubMed ID: 33777700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
    Iwaki M; Kessoku T; Ozaki A; Kasai Y; Kobayashi T; Nogami A; Honda Y; Ogawa Y; Imajo K; Yoneda M; Maeda A; Tanaka Y; Nakajima S; Ohno H; Usuda H; Kawanaka M; Kawaguchi T; Torimura T; Kage M; Hyogo H; Takahashi H; Eguchi Y; Aishima S; Wada K; Kobayashi N; Sumida Y; Saito S; Nakajima A
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2275-2284. PubMed ID: 33709477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice.
    de Sant'Ana LP; Ribeiro DJS; Martins AMA; Dos Santos FN; Corrêa R; Almeida RDN; Eberlin MN; Maurice CF; Magalhães KG
    Front Immunol; 2019; 10():2926. PubMed ID: 31998283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Schwimmer JB; Johnson JS; Angeles JE; Behling C; Belt PH; Borecki I; Bross C; Durelle J; Goyal NP; Hamilton G; Holtz ML; Lavine JE; Mitreva M; Newton KP; Pan A; Simpson PM; Sirlin CB; Sodergren E; Tyagi R; Yates KP; Weinstock GM; Salzman NH
    Gastroenterology; 2019 Oct; 157(4):1109-1122. PubMed ID: 31255652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.